Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

    Thumbnail
    Download
    Citations
    Scopus
    Web of Science
    Altmetric
    99
    94
    Author
    Tron, AE; Belmonte, MA; Adam, A; Aquila, BM; Boise, LH; Chiarparin, E; Cidado, J; Embrey, KJ; Gangl, E; Gibbons, FD; ...
    Date
    2018-12-17
    Source Title
    Nature Communications
    Publisher
    NATURE PUBLISHING GROUP
    University of Melbourne Author/s
    Gregory, Gareth; Johnstone, Ricky
    Affiliation
    Sir Peter MacCallum Department of Oncology
    University General
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., Gregory, G. P., Hargreaves, D., Hendricks, J. A., Johannes, J. W., Johnstone, R. W., Kazmirski, S. L., Kettle, J. G., Lamb, M. L., Matulis, S. M. ,... Hird, A. W. (2018). Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. NATURE COMMUNICATIONS, 9 (1), https://doi.org/10.1038/s41467-018-07551-w.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/253625
    DOI
    10.1038/s41467-018-07551-w
    Abstract
    Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs. Here, we describe AZD5991, a rationally designed macrocyclic molecule with high selectivity and affinity for Mcl-1 currently in clinical development. Our studies demonstrate that AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinical trial has been launched for evaluation of AZD5991 in patients with hematological malignancies (NCT03218683).

    Export Reference in RIS Format     

    Collections